Thrombotic Microangiopathy in Hematopoietic Cell Transplantation: an Update
Author Information
Author(s): Stavrou Evi, Hillard M. Lazarus
Primary Institution: Department of Medicine, University Hospitals Case Medical Center, Case Western Reserve University
Conclusion
Transplantation-associated thrombotic microangiopathy (TA-TMA) is a serious complication of hematopoietic cell transplantation that is influenced by various factors including conditioning regimens and immunosuppressive therapy.
Supporting Evidence
- TA-TMA incidence varies widely from 0.5% to 75% among studies.
- Mortality rates for TA-TMA range from 60% to 90%.
- Daclizumab has shown promising results in treating TA-TMA.
- Plasma exchange is generally not recommended for TA-TMA due to poor response rates.
- Risk factors for TA-TMA include the use of calcineurin inhibitors and acute graft-versus-host disease.
Takeaway
TA-TMA is a rare but serious problem that can happen after a bone marrow transplant, and it can be caused by the treatments used during the transplant.
Methodology
The article reviews various studies and reports on the incidence, risk factors, and treatment strategies for TA-TMA in hematopoietic cell transplantation.
Potential Biases
Potential biases may arise from the retrospective nature of many studies and the variability in diagnostic criteria used across different reports.
Limitations
The varying definitions and diagnostic criteria for TA-TMA complicate the understanding of its incidence and outcomes.
Participant Demographics
The study discusses a diverse population of hematopoietic cell transplant recipients, including both allogeneic and autologous transplants.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website